TimesSquare Capital Management LLC trimmed its position in Inogen, Inc (NASDAQ:INGN) by 16.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 418,200 shares of the medical technology company’s stock after selling 81,700 shares during the quarter. TimesSquare Capital Management LLC owned approximately 2.00% of Inogen worth $39,771,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in INGN. Schroder Investment Management Group acquired a new stake in shares of Inogen in the 2nd quarter valued at $132,000. Ameritas Investment Partners Inc. raised its holdings in shares of Inogen by 6.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,495 shares of the medical technology company’s stock valued at $143,000 after purchasing an additional 86 shares in the last quarter. Sei Investments Co. raised its holdings in shares of Inogen by 38.1% in the 2nd quarter. Sei Investments Co. now owns 1,606 shares of the medical technology company’s stock valued at $153,000 after purchasing an additional 443 shares in the last quarter. Victory Capital Management Inc. raised its holdings in shares of Inogen by 17.8% in the 2nd quarter. Victory Capital Management Inc. now owns 2,036 shares of the medical technology company’s stock valued at $194,000 after purchasing an additional 307 shares in the last quarter. Finally, Pinebridge Investments L.P. raised its holdings in shares of Inogen by 1.6% in the 2nd quarter. Pinebridge Investments L.P. now owns 2,143 shares of the medical technology company’s stock valued at $204,000 after purchasing an additional 33 shares in the last quarter. Institutional investors and hedge funds own 99.60% of the company’s stock.

In other Inogen news, EVP Matt Scribner sold 2,500 shares of the firm’s stock in a transaction on Thursday, October 12th. The shares were sold at an average price of $93.88, for a total transaction of $234,700.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Alison Bauerlein sold 15,000 shares of the firm’s stock in a transaction on Tuesday, October 10th. The stock was sold at an average price of $94.93, for a total transaction of $1,423,950.00. The disclosure for this sale can be found here. Insiders have sold a total of 88,000 shares of company stock worth $9,277,330 over the last quarter. 5.31% of the stock is owned by company insiders.

Shares of Inogen, Inc (NASDAQ INGN) opened at $124.39 on Friday. Inogen, Inc has a one year low of $60.02 and a one year high of $124.90. The company has a market cap of $2,596.02, a price-to-earnings ratio of 101.13, a P/E/G ratio of 5.23 and a beta of 0.99.

Inogen (NASDAQ:INGN) last announced its quarterly earnings results on Tuesday, November 7th. The medical technology company reported $0.33 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.29 by $0.04. Inogen had a net margin of 11.36% and a return on equity of 13.37%. The firm had revenue of $69.00 million for the quarter, compared to analyst estimates of $63.55 million. During the same period last year, the business earned $0.25 EPS. Inogen’s revenue for the quarter was up 26.8% compared to the same quarter last year. research analysts expect that Inogen, Inc will post 1.19 EPS for the current year.

A number of brokerages have recently weighed in on INGN. Zacks Investment Research upgraded shares of Inogen from a “hold” rating to a “buy” rating and set a $131.00 price objective on the stock in a report on Thursday, November 9th. Leerink Swann reiterated an “outperform” rating and set a $120.00 price target (up from $115.00) on shares of Inogen in a research note on Wednesday, November 8th. Needham & Company LLC lifted their price target on shares of Inogen from $108.00 to $125.00 and gave the stock a “strong-buy” rating in a research note on Wednesday, November 8th. Piper Jaffray Companies reiterated a “hold” rating and set a $90.00 price target on shares of Inogen in a research note on Tuesday, September 12th. Finally, BidaskClub upgraded shares of Inogen from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, August 8th. Three investment analysts have rated the stock with a hold rating, three have issued a buy rating and two have assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $103.14.

TRADEMARK VIOLATION NOTICE: This story was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.watchlistnews.com/timessquare-capital-management-llc-has-39-77-million-stake-in-inogen-inc-ingn/1726925.html.

About Inogen

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen, Inc (NASDAQ:INGN).

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.